2y ago we had a very similar situation, market value going down and down just before the year ended. Then in the new year there was gradual improvement. It looked as people wanted to sell because of tax purposes. The selling today may be caused because other reasons but while many other shares are on much higher levels it is easy to balance the losses in Prana.
2 y ago IMO Prana did not have very clear path forward. Prana told to do some short clinical studies with PBT2 but in the end nothing was done. Today IMO things are more clear. PBT434 has IMO better future when comparing with PBT2 2 years ago ( after Imagine study) and it can be very successful according the preclinical studies and the beginning of the phase 1. At least the plans are clear: orphan drug application and MSA phase 2 study after phase 1.
2y ago the understanding of the pathogenesis of both PD and AD were not so clear as they are today. Almost nobody talked about mitochondria or energy problems of the brain. According the preclinical results there is clear evidence that PBT434 has possibilities to help these patients (???). But nothing is clear before first phase 1 and then phase 2 results and of course this is the main reason why the stock price has been going down for months.
The "best" in the future of PBT434 IMO is that it seems to help the energy problem of all organs because it helps mitochondria by eliminating gradually accumulating iron which is hampering energy production and also causing mitochondrial fission and so ROS production. So possibly PBT434 can help many other mitochondrion diseases which earlier were not at all considered to be mitochondrion diseases: glaucoma, macula degeneration, osteoporosis, senile muscle atrophy, various heart disease, brain trauma etc. Critically ill people is the latest point on my list. Think about when do your cells need more energy than when they are just about to die ( iron hampering mitochondria).
